Recombinant B domain deleted porcine factor VIII for the treatment of bleeding episodes in adults with acquired hemophilia A

References

• Montgomery RR, Gill JC, Scott JP. Hemophilia and von Willebrand disease. In: Nathan and Oski's hematology of infancy and childhood Nathan DG, Orkin SH, Ginsburg D, Look AT, editors. Hemophilia and von Willebrand Disease in Hematology of Infancy and Childhood O.S. 6th edition. WB Saunders; Philadelphia, PA, USA: 2003. p. 1547-76
   Google Scholar
• Dimichele D. Chapter 11. Inhibitors to factor VIII-epidemiology and treatment. In: Textbook of Hemophilia. Lee CA, Berntorp EE, Hoots WK, Aledort LM, editors. Textbook of Hemophilia. Blackwell Publishing Ltd; Oxford, UK: 2005. p. 64-70
   Google Scholar
• Kessler CM, Asatiani E. Acquired inhibitors to factor VIII. In: Berntorp EE, Keith Hoots W, Lee CA, editor. Textbook of Hemophilia. Wiley-Blackwell; Oxford, UK: 2005. p. 86-90
   Google Scholar
• Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008;112(2):250-5
   PubMed Web of Science ®Google Scholar
• Baudo F, Collins P, Huth-Kϋthne A, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012;120(1):39-46
   PubMed Web of Science ®Google Scholar
• Collins PW. Treatment of acquired hemophilia A. J Thromb Haemost 2007;5(5):893-900
   PubMed Web of Science ®Google Scholar
• Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia 2007;13(5):451-61
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002;8(2):83-90
   PubMed Web of Science ®Google Scholar
• Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007;109(2):546-51
   PubMed Web of Science ®Google Scholar
• de Paula EV, Kavakli K, Mahlangu J, et al. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost 2012;10(1):81-9
   PubMed Web of Science ®Google Scholar
• Kavakli K, Makris M, Zulfikar B, et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006;95(4):600-5
   PubMed Web of Science ®Google Scholar
• Giangrande PL. Porcine factor VIII. Haemophilia 2012;18(3):305-9
   PubMed Web of Science ®Google Scholar
• Hay C, Lozier JN. Porcine factor VIII therapy in patients with factor VIII inhibitors. Adv Exp Med Biol 1995;386:143-51
   PubMedGoogle Scholar
• Negrier C. The use of porcine factor VIII in France. Semin Hematol 1994;31(2 Suppl 4):29-32
   PubMed Web of Science ®Google Scholar
• Griggs TR, Webster WP, Cooper HA, et al. Von Willebrand factor: gene dosage relationships and transfusion response in bleeder swine–a new bioassay. Proc Natl Acad Sci USA 1974;71:2087-90
   PubMed Web of Science ®Google Scholar
• Bahnak BR, Lavergne JM, Ferreira V, et al. Comparison of the primary structure of the functional domains of human and porcine von Willebrand factor that mediate platelet adhesion. Biochem Biophys Res Commun 1992;182:561-8
   PubMed Web of Science ®Google Scholar
• Brettler DB, Forsberg AD, Levine PH, et al. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med 1989;149(6):1381-5
   PubMedGoogle Scholar
• Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993;81(6):1513-20
   PubMed Web of Science ®Google Scholar
• Hay CR, Lozier JN, Lee CA, et al. Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: efficacy, patient selection, and side effects. Semin Hematol 1994;31(2 Suppl 4):20-5
   PubMed Web of Science ®Google Scholar
• Doering CB, Healey JF, Parker ET, et al. High level expression of recombinant porcine coagulation factor VIII. J Biol Chem 2002;277(41):38345-9
   PubMed Web of Science ®Google Scholar
• Healey JF, Lubin IM, Lollar P. The cDNA and derived amino acid sequence of porcine factor VIII. Blood 1996;88(11):4209-14
   PubMed Web of Science ®Google Scholar
• Bergman GE, Lillicrap D, Robinson P. Cross-over comparative study of tolerability, pharmacokinetics and efficacy of two forms of porcine Factor VIII in the canine model of hemophilia A. J Thromb Haemost 2005;3(Suppl 1): abstract no. PO835
   Google Scholar
• Kempton CL, Abshire TC, Deveras RA, et al. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia 2012;18(5):798-804
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Andreeva TA, Macfarlane DE, et al. A Phase II open-label study evaluating hemostatic activity, pharmacokinetics and safety of recombinant porcine factor VIII (OBI-1) in hemophilia a patients with alloantibody inhibitors directed against human FVIII. In: American Society of Hematology. Blood Atlanta, GA, USA; 2007
   Google Scholar
• Kruse-Jarres R, St-Louis J, Greist A, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia 2015;21(2):162-70
   PubMed Web of Science ®Google Scholar
• Kyhos B. FDA approves Baxter’s OBIZUR [antihemophilic factor (recombinant), procine sequence], for acquired hemophilia A. Baxter International Inc, Baxter website. 2014. p. 1-5
   Google Scholar
• Gomes H, Martinez F, Robelo B, et al. Delayed diagnosis of pulmonary embolism in a patient with a prior history of acquired haemophilia. Haemophilia 2015;21(Suppl 2):14-94; Abstract PP044
   Google Scholar
• Hay C. Porcine factor VIII: current status and future developments. Haemophilia 2002;8(Suppl 1):24-7
   PubMedGoogle Scholar
• Hay C, Lozier JN, Lee CA, et al. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey. Thromb Haemost 1996;75:25-9
   PubMed Web of Science ®Google Scholar